Notice NOT-OD-22-154 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-011 from the NIH Guide for Grants and Contracts. oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products. Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement. As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects. The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use. This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.

Notice NOT-OD-22-082 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-084 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-083 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-081 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-143 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-016 from the NIH Guide for Grants and Contracts

Notice NOT-NR-22-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-052 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.

Notice NOT-CA-22-094 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-165 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Funding Opportunity PAR-22-164 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Notice NOT-DA-22-069 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-015 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-020 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to inspire and support research to advance the drug and device development tools for ultimate submission to DDT or MDDT tool qualification program within either FDAs CDER or CDRH. The funding will be used to further the development of tools that, once qualified, will be available to fill unmet needs in SUD biomedical product development. This FOA ultimately aims to bring innovative treatments to SUD patients faster.

Funding Opportunity RFA-DA-23-019 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to inspire and support research to advance the drug and device development tools for ultimate submission to DDT or MDDT tool qualification program within either FDAs CDER or CDRH. The funding will be used to further the development of tools that, once qualified, will be available to fill unmet needs in SUD biomedical product development. This FOA ultimately aims to bring innovative treatments to SUD patients faster.

Funding Opportunity RFA-DK-22-001 from the NIH Guide for Grants and Contracts. This U2C funding opportunity announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 2 diabetes research (SEIC-T2D). A primary goal of the SEIC-T2D is to accelerate equitable engagement of diverse stakeholders in T2D research, particularly those from diverse communities that experience diabetes-related health disparities, and systems that impact their health. The SEIC-T2D will provide highly specialized research resources to support investigators by fully embedding communities, patients, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T2D will also establish a network consisting of diverse, multidisciplinary research investigators with expertise in T2D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T2D prevention and treatment.

Notice NOT-OD-22-155 from the NIH Guide for Grants and Contracts